These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 25571722)

  • 1. [Effect of human concentration nucleoside transporters 1 and multi-drug resistance protein 4 gene polymorphism on response of chronic hepatitis B to nucleoside analogues treatment].
    Wang WZ; Lu LX; Li DJ; Lu JJ; He M; Liu C; Tang H; Wang LC
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Nov; 45(6):950-5. PubMed ID: 25571722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABCC4, ABCC5 and SLC28A1 polymorphisms: host genome on responses of chronic hepatitis B patients with entecavir treatment.
    Yuan M; Wang W; Chen H; Lu J; He M; Liu C; Tang H; Wang L
    Antivir Ther; 2016; 21(8):689-696. PubMed ID: 27354267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Short-term results of telbivudine versus entecavir treatments in HBeAg-positive chronic hepatitis B patients in China].
    Shi KQ; Zhang DZ; Guo SH; He H; Wang ZY; Shi XF; Zeng WQ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2008 Sep; 16(9):641-5. PubMed ID: 18822200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
    Pan HY; Pan HY; Song WY; Zheng W; Tong YX; Yang DH; Dai YN; Chen MJ; Wang MS; Huang YC; Zhang JJ; Huang HJ
    J Viral Hepat; 2017 Nov; 24 Suppl 1():29-35. PubMed ID: 29082652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study.
    Guo X; Wu J; Wei F; Ouyang Y; Li Q; Liu K; Wang Y; Zhang Y; Chen D
    Int J Antimicrob Agents; 2018 Aug; 52(2):201-209. PubMed ID: 29654894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
    Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
    J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug resistance protein 4 is a critical protein associated with the antiviral efficacy of nucleos(t)ide analogues.
    Liu W; Song H; Chen Q; Xu C; Zhang W; Liu Y; Wang B; Xu D; Lu M; Yang D; Zheng X
    Liver Int; 2016 Sep; 36(9):1284-94. PubMed ID: 26931636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients].
    Huang J; Chen XP; Chen XF; Chen WL; Chen R; Ma XJ; Luo XD
    Zhonghua Gan Zang Bing Za Zhi; 2011 Mar; 19(3):178-81. PubMed ID: 21586234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a].
    Luo XD; Chen XP; Chen R; Chen XF; Huang J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):241-5. PubMed ID: 27470620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nucleoside analogues for acute-on-chronic liver failure associated with hepatitis B virus infection: a 24-month survival analysis].
    Gao H; Lin M; Pan C; Lin T; Wang X; Zhou R; Li X
    Zhonghua Gan Zang Bing Za Zhi; 2015 Jan; 23(1):17-22. PubMed ID: 25751381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early hepatitis B viral DNA clearance predicts treatment response at week 96.
    Fu XY; Tan DM; Liu CM; Gu B; Hu LH; Peng ZT; Chen B; Xie YL; Gong HY; Hu XX; Yao LH; Xu XP; Fu ZY; He LQ; Li SH; Long YZ; Li DH; Gu JL; Peng SF
    World J Gastroenterol; 2017 Apr; 23(16):2978-2986. PubMed ID: 28522916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD; Chen XF; Zhou Y; Chen XP
    J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.
    Tsai MC; Lee CM; Chiu KW; Hung CH; Tung WC; Chen CH; Tseng PL; Chang KC; Wang JH; Lu SN; Yen YH; Hu TH
    J Antimicrob Chemother; 2012 Mar; 67(3):696-9. PubMed ID: 22174039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Entecavir: a new nucleoside analogue for the treatment of chronic hepatitis B.
    Rivkin A
    Drugs Today (Barc); 2007 Apr; 43(4):201-20. PubMed ID: 17460784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients.
    Lin CC; Bair MJ; Chen CJ; Lee KH; Chen MJ; Liu CY; Chang CW; Hu KC; Liou TC; Lin SC; Wang HY; Chu CH; Shih SC; Wang TE
    Kaohsiung J Med Sci; 2016 Jan; 32(1):10-5. PubMed ID: 26853169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
    Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
    Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of nucleoside antivirals in chronic hepatitis B.
    Duong A; Mousa SA
    Drugs Today (Barc); 2009 Oct; 45(10):751-61. PubMed ID: 20069139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.